We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression platform to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and lower cost to patients and the healthcare system. We believe that C1 will become an alternative protein expression host cells (other than CHO, and E.coli) for the high yield/low cost production of mAbs, bi-specific and multi-specific antibodies, Fc-fusion and other types of therapeutic antibodies, antibody fragments, virus like particles, and vaccines.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):